Pediadermics Eczema 2

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the temporary relief of minor skin irritations, inflammation, and rashes associated with eczema.

There are no teratogenic or nonteratogenic effects reported for this medication.

Dosage and Administration

Healthcare professionals are advised to consult a physician prior to administering this product to children under 2 years of age. Prior to use, the bottle should be shaken vigorously at least two times to ensure proper mixing of the formulation.

The product should be applied by holding the bottle approximately 2 inches away from the affected skin. A minimum of two full pump sprays should be dispensed directly onto the areas exhibiting flaring, characterized by redness, roughness, or itchiness. It is essential to cover the affected areas completely and extend the application about two finger-widths onto the surrounding normal skin.

The recommended frequency of application is twice daily, and treatment should not exceed a duration of two consecutive weeks. If the rash persists beyond this two-week period, the patient should seek further evaluation from a physician.

Contraindications

The product is contraindicated for the treatment of diaper rash without prior consultation with a physician. This precaution is necessary to ensure appropriate management and to avoid potential complications associated with untreated or improperly treated conditions.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to avoid ingestion of the product. In the event of accidental swallowing, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients should be instructed to discontinue use and consult their healthcare provider if their condition worsens or if any irritation occurs. Additionally, if symptoms persist for more than two weeks, it is essential to stop using the product and seek medical advice to ensure appropriate management and evaluation of the underlying condition.

Side Effects

Patients should be aware that the product is intended for external use only. In clinical practice, it is important to monitor for any adverse reactions that may arise during treatment.

Participants are advised to stop using the product and consult a healthcare professional if their condition worsens or if irritation occurs. Additionally, if symptoms persist for more than two weeks, it is recommended that patients seek medical advice. These precautions are essential to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Pediadermics Eczema 2 (hydrocortisone). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 2 years of age should be evaluated by a physician prior to use. It is essential to keep the product out of reach of children to prevent accidental ingestion. In the event of swallowing the product, immediate medical assistance should be sought, or contact with a Poison Control Center is advised.

Geriatric Use

There is no specific information regarding the use of Pediadermics Eczema 2 hydrocortisone spray in geriatric patients. Therefore, healthcare providers should exercise caution when prescribing this medication to elderly patients. It is advisable to monitor for potential adverse effects and consider individual patient factors, including comorbidities and concurrent medications, when determining the appropriateness of treatment in this population. Additionally, since no dosage adjustments or specific safety considerations for geriatric patients are outlined, clinicians should remain vigilant and adjust treatment as necessary based on the clinical response and tolerance of the elderly patient.

Pregnancy

There are no specific statements regarding the use of this product during pregnancy, including any safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this product to pregnant patients and weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, severe drowsiness, confusion, respiratory distress, or any other unusual clinical manifestations.

Management of an overdose should be tailored to the individual patient and may involve supportive care, including monitoring vital signs and providing symptomatic treatment as necessary. In cases of significant overdose, consultation with a poison control center or a medical toxicologist is recommended to determine the most appropriate course of action.

It is crucial for healthcare professionals to educate patients about the importance of adhering to prescribed dosages and to provide guidance on what to do in the event of a suspected overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: skin irritation, allergic reactions, and contact dermatitis. These events have been documented in the context of routine pharmacovigilance activities.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion. In the event that the product is swallowed, patients should seek medical help or contact a Poison Control Center immediately.

Patients should be instructed to discontinue use and consult a doctor if their condition worsens or if any irritation occurs. Additionally, if symptoms persist for more than two weeks, patients are encouraged to stop using the product and seek medical advice.

While using this product, it is important for patients to avoid direct contact with the eyes, mouth, and genital or anal areas to prevent adverse reactions. Furthermore, healthcare providers should inform patients that the product should not be used for the treatment of diaper rash without prior consultation with a physician.

Storage and Handling

The product is supplied in a container that must be stored at room temperature. It is essential to protect the product from light exposure to maintain its integrity. The bottle should be kept in an upright position at all times. Once opened, the product must be discarded to ensure safety and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Pediadermics Eczema 2, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)